Bruker Corporation reported fourth quarter (Q4) 2025 revenues of USD 977.2 million, with results flat year-over-year and a reported organic decrease of approximately 5 percent. Q4 2025 GAAP diluted earnings per share $(EPS)$ were USD 0.10, while non-GAAP diluted EPS were USD 0.59. For the full year (FY) 2025, revenues reached USD 3.44 billion, representing a 2 percent increase year-over-year, although organic revenues declined approximately 4 percent. FY 2025 GAAP diluted loss per share was USD 0.15, while non-GAAP diluted EPS totaled USD 1.83. Bruker Scientific Instruments segment reported Q4 2025 revenues of USD 907.7 million, a decrease of 0.4 percent year-over-year, with organic revenues down 5.1 percent. The Bruker Energy & Supercon Technologies segment recorded Q4 2025 revenues of USD 71.5 million, down 0.8 percent year-over-year, with an organic decrease of 5.1 percent. The company’s Q4 2025 GAAP operating income was USD 76.3 million. Non-GAAP operating income for the quarter was USD 153.5 million, with a non-GAAP operating margin of 15.7 percent. Bruker’s management noted that despite a challenging 2025, including headwinds from academic funding, tariffs, and currency effects, the company’s Q4 revenues exceeded expectations, supported by a recovery in biopharma and industrial research markets and improved semiconductor orders. The Scientific Instruments segment achieved a book-to-bill ratio above 1.0 for the second consecutive quarter, while the BEST segment secured strong multi-year orders. Bruker announced ongoing cost-saving initiatives in response to margin performance. For fiscal year 2026, Bruker initiated guidance for revenues between USD 3.57 billion and USD 3.60 billion, expecting year-over-year growth of 4 to 5 percent and organic growth of 1 to 2 percent. Non-GAAP EPS is projected in the range of USD 2.10 to USD 2.15, representing an increase of 15 to 17 percent, including an estimated 8 percent foreign exchange headwind.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bruker Corporation published the original content used to generate this news brief on February 12, 2026, and is solely responsible for the information contained therein.